Article
Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
Breast cancer research and treatment - 1 Nov 2015
Oesterreich Steffi, Henry N Lynn, Kidwell Kelley M, Van Poznak Catherine H, Skaar Todd C, Dantzer Jessica, Li Lang, Hangartner Thomas N, Peacock Munro, Nguyen Anne T, Rae James M, Desta Zeruesenay, Philips Santosh, Storniolo Anna M, Stearns Vered, Hayes Daniel F, Flockhart David A
Abstract excerpt
Adjuvant therapy for hormone receptor (HR) positive postmenopausal breast cancer patients includes aromatase inhibitors (AI). While both the non-steroidal AI letrozole and the steroidal AI exemestane decrease serum estrogen concentrations, there is evidence that exemestane may be less detrimental to bone. We hypothesized that single nucleotide polymorphisms (SNP) predict effects of AIs on bone turnover. Early...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.